Alector operates within the highly competitive biotechnology and biopharmaceutical sector, specifically focusing on immuno-neurology and neurodegenerative disease treatments. Its primary competitors include various clinical-stage and established pharmaceutical firms developing therapeutic antibodies or gene therapies targeting central nervous system disorders, Alzheimer's disease, and cognitive decline. Companies ranging from specialized neurology biotech startups to major global drug manufacturers often pursue parallel pathways in antibody engineering and blood-brain barrier penetration technologies.